XML 44 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
May 31, 2023
Feb. 28, 2019
Mar. 31, 2025
Mar. 31, 2024
Jun. 30, 2023
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     $ 52,443,000 $ 41,873,000  
Immune Medicine Service Revenue          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     3,600,000 4,700,000  
Medicare Reimbursements          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement     2,000,000 $ 1,500,000  
MRD Development Agreements | Maximum          
Disaggregation Of Revenue [Line Items]          
Additional milestone payment receivable     412,000,000    
Genentech Collaboration Agreement          
Disaggregation Of Revenue [Line Items]          
Revenue from collaboration agreement         $ 7,700,000
Non-refundable upfront payments received   $ 300,000,000.0 300,000,000.0    
Additional transaction price of regulatory milestone $ 10,000,000        
Expected revenue through milestone payments     $ 1,800,000,000    
Genentech Collaboration Agreement | Regulatory Milestones          
Disaggregation Of Revenue [Line Items]          
Additional transaction price of regulatory milestone $ 10,000,000.0        
Genentech Collaboration Agreement | Maximum          
Disaggregation Of Revenue [Line Items]          
Revenue recognition expected period     10 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments     $ 65,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments     300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones          
Disaggregation Of Revenue [Line Items]          
Expected revenue through milestone payments     $ 1,430,000,000    
Genentech Collaboration Agreement | Minimum          
Disaggregation Of Revenue [Line Items]          
Revenue recognition expected period     9 years